Intelligent Ultrasound Share Discussion Threads

[chester9] 27/2/2024 17:15

Working with Gates foundation at scale over three countries gives real credibility.

[eeza] 27/2/2024 16:12

RNS

ScanNav

[clocktower] 24/2/2024 15:11

Trouble with this is the lack of liquidity but I feel the prospects could be good but I guess when it starts to move it could take a big leap upwards.

[40 fathoms] 09/2/2024 10:09

BM@ can I suggest you wait to break your rule, if this goes the way we think it will you will still make a lot of money buying more shares at 12p or 15p. Wait till they confirm they are going to be profitable and then top up.

[40 fathoms] 09/2/2024 10:06

Hi Bamboo,

It is all starting to come in to focus now and I think we can move beyond mosaic theory to understand that they are targeting the known requirements of the US DoD for an AI driven regional anasthesisa product that can be deployed in the field. We also know that the US DoD has a RFP out for 6,000 battlefield POCUS Ultrasound machines with a deadline at the end of March. Additionally we also know that, currently, only we meet the DOD criteria for AI guided nerve block capability.

I think it is reasonable to assume that they will be either looking to integrate our software in to these machines (most likely in my opinion) or looking to place a companion order for ScanNav PNB product. Obviously in addition to the PNB product they will also need a simulation and training product to ensure they get the best out of that capability.

As the CEO says today I have put the key bit in CAPS.

"We hope this new version of NeedleTrainer will support clinicians in more remote areas and help to open up additional markets for our simulators AND AI SOFTWARE in the US, UK and through our resellers around the world as we continue to grow our classroom-to-clinic business."

For the US alone over the next 18 months I reckon this is a GBP 5 million opportunity (100% gross margin) opportunity for the licencing of ScanNav PNB software and a GBP 15 million (60% gross margin) opportunity over 5 years for the training products, maintenance and upgrades. I also reckon if the US picks this up it will also get picked up by other NATO militaries and that could be worth an additional 50% to 100% of the US orders. You could also then also start to look at BARDA, US Navy, certain aid agencies, air ambulance services etc for more orders.

I think we should know by this time next year if the US DoD is going to pick this up or not.

[bmcollins] 09/2/2024 10:04

@bamboo
@40f

I don't wish to sound like an echo chamber here but with that update and given the recent weakness of the share price I am a little bemused as to why there has been so little reaction, i.e. no change in the 8.5p-9p price and very few, only small trades done as well.
I guess it is better than the 10% to 20% mark-downs many AIM shares have suffered after their updates recently but I read a lot of good news in their RNS today.
I'm pretty much up to my maximum in what I'd ever put into a stock of this nature but with profitability apparently very close, GEHC & Gates foundation backing it, to me the upside looks much more likely than the downside so I'm seriously thinking about breaking one of my own rules and doubling up.

[bamboo2] 09/2/2024 09:13

Hi 40F, if you get a mo, and you think it appropriate, would you revisit your post 216, update and repost in respect of todays RNSNON?

[bamboo2] 09/2/2024 08:01

Intelligent Ultrasound launches portable NeedleTrainer Plus



PRESS RELEASE 9 February 2024: Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, is pleased to announce that it has launched a portable NeedleTrainer Plus ultrasound-guided needling training simulator.



Aimed at training ultrasound-guided needling in military field-based hospitals, as well as clinical networks outside major urban areas, the system is packed in a robust, portable pelicase complete with a GE HealthCare Vscan handheld ultrasound device.



NeedleTrainer is a first of its kind training simulator that uses a retractable needle and virtual image overlays to simulate needling on a live volunteer, using a live ultrasound scan. This enables trainees to develop hand-eye coordination, optimum positioning, and accuracy in ultrasound-guided interventional procedures in a realistic clinical environment with minimal risk.



The system is part of a portfolio that includes Intelligent Ultrasound's latest ScanNav™ Anatomy Peripheral Nerve Block, an AI technology that helps healthcare professionals to identify and label anatomy in live ultrasound images in preparation for ultrasound-guided regional anesthesia and analgesia. The AI software automatically highlights the anatomy associated with the most common peripheral nerve blocks.



Ultrasound-guided peripheral nerve block injections are increasingly used for pain relief after surgery and trauma. Data from a study published in the British Journal of Anaesthesia in September showed that, when ScanNav™ Anatomy PNB was available, there was a 40.4% relative increase in the number of peripheral nerve blocks used in trauma cases, without a decrease in quality of care.



Stuart Gall, CEO at Intelligent Ultrasound said:

"We hope this new version of NeedleTrainer will support clinicians in more remote areas and help to open up additional markets for our simulators and AI software in the US, UK and through our resellers around the world as we continue to grow our classroom-to-clinic business."

[eeza] 09/2/2024 07:27

Military application mentioned.

[chester9] 06/2/2024 13:47

Ultrasound Highlights• Organic revenue growth* declined due to a challenging comparison against the same period last year• EBIT margin decreased YoY primarily due to investments(2) includingCaption Health• R&D driving greater digital/software capabilities across Ultrasound for key 2023 launches including Vscan Air SLand Venue Family with CaptionGuidance• Well-positioned with recent customer commitments and interest in new product introductions

[chester9] 06/2/2024 13:36

On GEHC Q4 call. Nice early mention of Gates foundation support for ultrasound.

[40 fathoms] 06/2/2024 13:11

They have already told us what cash was at 31.12.23 in the TU.

Cash at bank on 31 December 2023 was £3.0m (30 June 2023: £3.3m).

[clocktower] 06/2/2024 12:19

Could be the start of a bull run I guess.

[parsons4] 06/2/2024 11:03

Just topped up, I like what I am hearing here !! but the market is not keeping up with the news imho of course.

[clocktower] 06/2/2024 09:06

Cash at end of 2022 was £7.2m - what will it at end of 2023?

More cash needed or will it squeeze by and manage without the need for a further raise?

Tempted to take a chance and have a punt.

[bamboo2] 06/2/2024 07:15

Chester9, we may get more information today as GEHC report Q4 and FY23 later on.

=============================

GEHC Q4 & FY2023 13:30 GMT 6 February 2024

GE HealthCare to Announce Fourth Quarter and Full Year 2023 Results on February 6, 2024
January 18, 2024

CHICAGO--(BUSINESS WIRE)--Jan. 18, 2024-- GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 6, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website.

[chester9] 05/2/2024 18:17

Price reaction has been overdone. 24 revenue forecast 14-17m with no need for a fund raise to get to profitability with positive cash flow. Price may drift though until results confirmed with trading update in April

[bamboo2] 05/2/2024 17:47

IUG feed on Twitter just featured this link to Gates Foundation.

AI-enabled ultrasound

[babbler] 31/1/2024 13:24

https://www.dailymail.co.uk/health/article-13013517/scan-available-NHS-end-years-misery-women-suffering-endometriosis-patients-ultrasound-test-experts.html

[bmcollins] 27/1/2024 12:01

@40 Fathoms
Just watched it, thanks for drawing our attention to it as I found it very interesting.
It will be interesting to see if anything is mentioned on Feb 6...

[40 fathoms] 27/1/2024 03:03

Worth watching the whole video but most of it is not new. However, I have teed the video to the point where he mentions a military application for Needle trainer. This is the first confirmation that they are adapting their PNB products for military use. We also know from my previous posts on this issue that the US DOD is in the market for both PNB training and field deployable PNB ultrasound guidance products.

[40 fathoms] 22/1/2024 09:03

So it looks like they did a bit of a refresh of the website over the weekend and it is full of lots of new insights.

[40 fathoms] 20/1/2024 10:06

@bamboo - yes, there is now quite a product pipeline. We have filed a number of patents in the last 18 months where we, do not yet, understand exactly what the product might be. We also know there will be at least 3 additional products under the GEHC deal, the 8 week and 30 week protocol scans and then whatever was covered under the the second agreement that was signed with GEHC. In addition we have the gestational age product which looks to be close to out licensing to OEMs and we also know we have one or more liver products under development.

@bmcollins - yes, unloved is a very fair assessment. I think many investors in general are still shell shocked and remain risk adverse and currently they do not have sufficient confidence that IUG will not comeback to market for cash. I think these concerns should dissipate over the next 4 to 6 months and the natural order of things will be restored. With a fair wind and the magic of the J curve, we could easily be looking at an EBIT of @GBP 3 million in 2025 and @GBP 6 million in 2026. A 20x to 40x P/E seem like a reasonable range, in my view, if that were to come to pass.

[bamboo2] 19/1/2024 18:33

GEHC Q4 & FY2023 13:30 GMT 6 February 2024

GE HealthCare to Announce Fourth Quarter and Full Year 2023 Results on February 6, 2024
January 18, 2024

CHICAGO--(BUSINESS WIRE)--Jan. 18, 2024-- GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 6, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at The earnings release, accompanying financial information, and webcast replay will also all be posted at the same link on the GE HealthCare Investor Relations website.